ESBC
ZNTL icon

E.S. Barr & Co’s Zentalis Pharmaceuticals ZNTL Stock Holding History

E.S. Barr & Co’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$534K Hold
110,000
– – 0.03% 73
2026
Q1 		$257K Buy
110,000
+52,500
+91% +$136K 0.02% 99
2025
Q4 		$77.6K Buy
57,500
+17,500
+44% +$25.5K ﹤0.01% 132
2025
Q3 		$60.4K Hold
40,000
– – ﹤0.01% 114
2025
Q2 		$46.4K Hold
40,000
– – ﹤0.01% 116
2025
Q1 		$63.6K Buy
+40,000
New +$86.3K ﹤0.01% 104

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

E.S. Barr & Co's ZNTL Position: Q2 2026 in Review

E.S. Barr & Co held its Zentalis Pharmaceuticals (ZNTL) position steady in Q2 2026 at 110,000 shares worth $534K. The position accounts for 0.03% of the portfolio, ranked #73.

E.S. Barr & Co first reported a position in ZNTL in Q1 2025 and has held it in 6 quarters since. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • E.S. Barr & Co held 110,000 shares of Zentalis Pharmaceuticals worth $534K as of Q2 2026.
  • E.S. Barr & Co left its Zentalis Pharmaceuticals share count unchanged in Q2 2026.
  • Zentalis Pharmaceuticals made up 0.03% of E.S. Barr & Co's portfolio in Q2 2026, its #73 holding.
  • E.S. Barr & Co first reported a position in Zentalis Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on E.S. Barr & Co's 13F filing for Q2 2026, filed 13 Aug 2026.